ClinicalTrials.gg
CompletedNCT06088043Updated Oct 24, 2025

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

A Phase 3 interventional study of TAK-279 and Placebo in Plaque Psoriasis, sponsored by Takeda. Completed at 132 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-24.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 9 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Oct 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
693
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Enrollment
56th of 673
693 · median 77
Started
2023
with 31 others
Phase 3
188 of 764
6 open now
Registered
697th of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 56th largest by enrollment of the 673 interventional ones that give a count, is one of 32 that started in 2023, is one of 188 in phase 3, and was the 697th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 61 weeks.

Read the detailed description

The drug being tested in this study is called TAK-279. TAK-279 is being tested to treat people with moderate to severe plaque psoriasis.

The study will enroll approximately 600 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the following treatment groups in a ratio of 3:1:1 to receive TAK-279, placebo, or apremilast which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

  1. TAK-279
  2. Placebo
  3. Apremilast

This multi-center trial will be conducted worldwide. Participants will go through a screening process to make sure they meet the rules for taking part in the study. This will take up to 35 days. If participants meet the study rules, they will be treated for up to 52 weeks (1 year). There will be a safety follow-up visit 4 weeks after their last day of treatment.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Drug Therapy
  • Latitude Psoriasis 1, Latitude Research Program
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Plaque psoriasis for at least 6 months.
  2. Moderate to severe disease.
  3. Candidate for phototherapy or systemic therapy.

Exclusion criteria

Exclusion Criteria:

  1. Other forms of psoriasis.
  2. History of recent infection.
  3. Prior exposure to TAK-279 or active comparator.

Other protocol defined inclusion/exclusion criteria apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
693 participants (actual)

Study arms

  • Experimental
    TAK-279

    Drug: TAK-279

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Active comparator
    Apremilast

    Drug: Apremilast

Interventions

  • Specified drug on specified days.

  • DrugPlacebo

    Specified drug on specified days.

  • Specified drug on specified days.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) with a >=2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Placebo

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' and 'Almost clear' will include all participants who score a 0 or 1.

    Time frame: Baseline, Week 16

  2. Percentage of Participants Achieving >=75% Improvement from Baseline in Psoriasis Area and Severity Index (PASI) Score (PASI-75 Response) at Week 16 Comparing TAK-279 Against Placebo

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Percentage of Participants Achieving 90% Improvement from Baseline in PASI (PASI-90 Response) at Week 16 Comparing TAK-279 Against Placebo

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Baseline, Week 16

  2. Percentage of Participants Achieving an sPGA of Clear (0) at Week 16 Comparing TAK-279 Against Placebo

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. Higher scores indicate worsening. 'Clear' will include all participants who score a 0.

    Time frame: Week 16

  3. Percentage of Participants Achieving PASI-100 at Week 16 Comparing TAK-279 Against Placebo

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing 100% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Week 16

  4. Percentage of Participants Achieving a Scalp-specific Physician's Global Assessment (ssPGA) of Clear (0) or Almost Clear (1) with a >=2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Placebo

    ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions will be evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicate worsening.

    Time frame: Baseline and Week 16

  5. Percentage of Participants with a Baseline Dermatology Life Quality Index (DLQI) Score >=2 who Achieve DLQI Score of 0 or 1 at Week 16 Comparing TAK-279 Against Placebo

    The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's quality of life (QoL) during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicate: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life).

    Time frame: Week 16

  6. Percentage of Participants with a Baseline Psoriasis Symptoms and Signs Diary (PSSD) >=1 who Achieve Weekly Mean PSSD Symptom Score of 0 at Week 16 Comparing TAK-279 Against Placebo

    The PSSD is an 11-item validated questionnaire that assesses symptoms (itch, pain, stinging, burning, and skin tightness) and participant-observable signs (skin dryness, cracking, scaling, shedding/flaking, redness, and bleeding) of moderate-to-severe plaque psoriasis. These symptoms and signs will be evaluated by asking participants to assign a numerical score representing of worst intensity over the last 24-hour on a scale from 0 to 10, with 0 indicating absence of symptoms or signs and 10 indicating worst imaginable symptoms or signs. The PSSD is a composite score calculated based on the scores for each question that can range between 0 and 100. A higher score indicates more severe disease.

    Time frame: Week 16

  7. Change from Baseline in Nail Psoriasis Severity Index (NAPSI) at Week 16 Among Participants with Nail Involvement at Baseline Comparing TAK-279 Against Placebo

    The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lunula, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each nail will be scored for both nail matrix and nail bed psoriasis for each quadrant (ranging from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores indicate more severe psoriasis.

    Time frame: Baseline and Week 16

  8. Change from Baseline in Body Surface Area (BSA) Affected by Psoriasis at Week 16 Comparing TAK-279 Against Placebo

    Psoriasis BSA will be assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represents 1% BSA. The sum of handprints equates to the total surface area of involvement.

    Time frame: Baseline and Week 16

  9. Percent Change from Baseline in Body Surface Area (BSA) Affected by Psoriasis at Week 16 Comparing TAK-279 Against Placebo

    Psoriasis BSA will be assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represents 1% BSA. The sum of handprints equates to the total surface area of involvement.

    Time frame: Baseline and Week 16

  10. Percentage of Participants Achieving a Physician's Global Assessment (PGA) of the Hands and/or Feet of Clear (0) or Almost Clear (1) with a >=2-Point Decrease From Baseline at Week 16 Comparing TAK-279 Against Placebo

    PGA is a 5-point scale and a score of 0 to 4 should be assigned, based on the category that best describes the severity of active psoriasis of the participant's hands and/or feet (palmoplantar), where 0=clear and 4=severe. Higher scores indicate worsening of severity. It will be evaluated for participants with the presence of active hand or foot psoriasis on Day 1.

    Time frame: Baseline and Week 16

  11. Change from Baseline in DLQI at Week 16 Comparing TAK-279 Against Placebo

    The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicate: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life). It will be evaluated for participants with a baseline DLQI score \>=2.

    Time frame: Baseline and Week 16

  12. Change from Baseline in the Short Form-36 Health Survey (SF-36) Version 2 Scores at Week 16 Comparing TAK-279 Against Placebo

    The SF-36 is a self-administered, validated questionnaire designed to measure generic health-related QoL. This 36-item questionnaire measures 8 domains, including physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health, physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Two summary scores, including the physical component summary (PCS) and mental component summary (MCS), will be calculated ranging from 0 (worst) to 100 (best). Higher scores indicate better QoL.

    Time frame: Baseline and Week 16

  13. Change from Baseline in the EuroQoL 5-Dimension 5-level Questionnaire (EQ-5D-5L) Scores at Week 16 Comparing TAK-279 Against Placebo

    EQ-5D-5L includes 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and 5 response levels for each domain (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems). The scores in the 5 dimensions will be summarized into a health state index score. The health state index value is a single value on a scale from less than 0 to 1 (negative values are valued as worse than dead) with higher scores indicating better health; 0=a health state equivalent to death, and 1=perfect health.

    Time frame: Baseline and Week 16

  14. Change in Work Productivity and Activity Impairment-Psoriasis (WPAI-PSO) Questionnaire Scores at Week 16 Comparing TAK-279 Against Placebo

    The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism and impairment in activities performed outside of work. Each WPAI score will be expressed as impairment percentages (0-100) with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.

    Time frame: Week 16

  15. Percentage of Participants Achieving an sPGA of Clear (0) or Almost Clear (1) with a >=2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Apremilast

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. Higher scores indicate worsening. 'Clear' and 'Almost clear' will include all participants who score a 0 or 1.

    Time frame: Baseline and Week 16

  16. Percentage of Participants Achieving PASI-75 at Week 16 Comparing TAK-279 Against Apremilast

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Week 16

  17. Percentage of Participants Achieving PASI-90 at Week 16 Comparing TAK-279 Against Apremilast

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Week 16

  18. Percentage of Participants Achieving an sPGA of Clear (0) or Almost Clear (1) with a >=2-Point Decrease from Baseline at Week 24 Comparing TAK-279 Against Apremilast

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' and 'Almost clear' will include all participants who score a 0 or 1.

    Time frame: Baseline and Week 24

  19. Percentage of Participants Achieving PASI-75 at Week 24 Comparing TAK-279 Against Apremilast

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Week 24

  20. Percentage of Participants Achieving PASI-90 at Week 24 Comparing TAK-279 Against Apremilast

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Week 24

  21. Change from Baseline in Weekly Mean PSSD Symptom Score at Week 16 Comparing TAK-279 Against Apremilast

    The PSSD is an 11-item validated questionnaire that assesses symptoms (itch, pain, stinging, burning, and skin tightness) and participant-observable signs (skin dryness, cracking, scaling, shedding/flaking, redness, and bleeding) of moderate-to-severe plaque psoriasis. These symptoms and signs will be evaluated by asking participants to assign a numerical score representing of worst intensity over the last 24-hour on a scale from 0 to 10, with 0 indicating absence of symptoms or signs and 10 indicating worst imaginable symptoms or signs. The PSSD is a composite score calculated based on the scores for each question that can range between 0 and 100. A higher score indicates more severe disease.

    Time frame: Baseline and Week 16

  22. Percentage of Participants Achieving an ssPGA of Clear (0) or Almost Clear (1) with a >=2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Apremilast

    ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions will be evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicate worsening.

    Time frame: Week 16

  23. Percentage of Participants Achieving PASI-100 at Week 16 Comparing TAK-279 Against Apremilast

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing 100% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Week 16

  24. Percentage of Participants Achieving PASI-100 at Week 24 Comparing TAK-279 Against Apremilast

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing 100% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Week 24

  25. Percentage of Participants Achieving an sPGA of Clear (0) at Week 16 Comparing TAK-279 Against Apremilast

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' will include all participants who score a 0.

    Time frame: Week 16

  26. Percentage of Participants with a Baseline DLQI Score >=2 who Achieve DLQI Score of 0/1 at Week 16 Comparing TAK-279 Against Apremilast

    The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicate: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life).

    Time frame: Week 16

  27. Percentage of Participants with a Baseline PSSD >=1 who Achieve a Weekly Mean PSSD Symptom Score of 0 at Week 16 Comparing TAK-279 Against Apremilast

    The PSSD is an 11-item validated questionnaire that assesses symptoms (itch, pain, stinging, burning, and skin tightness) and participant-observable signs (skin dryness, cracking, scaling, shedding/flaking, redness, and bleeding) of moderate-to-severe plaque psoriasis. These symptoms and signs will be evaluated by asking participants to assign a numerical score representing of worst intensity over the last 24-hour on a scale from 0 to 10, with 0 indicating absence of symptoms or signs and 10 indicating worst imaginable symptoms or signs. The PSSD is a composite score calculated based on the scores for each question that can range between 0 and 100. A higher score indicates more severe disease.

    Time frame: Week 16

  28. Change from Baseline in NAPSI, Among Participants with Nail Involvement at Baseline at Weeks 16 and 24 Comparing TAK-279 Against Apremilast

    The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lunula, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each nail will be scored for both nail matrix and nail bed psoriasis for each quadrant (ranging from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores indicate more severe psoriasis.

    Time frame: Baseline, Weeks 16 and 24

  29. Percentage of Participants Achieving an ssPGA of Clear (0) or Almost Clear (1) with a >=2-Point Decrease from Baseline at Week 24 Comparing TAK-279 Against Apremilast

    ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions will be evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicate worsening.

    Time frame: Baseline and Week 24

  30. Change from Baseline in DLQI at Weeks 16 and 24 Comparing TAK-279 Against Apremilast

    The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicate: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life).

    Time frame: Baseline, Weeks 16 and 24

  31. Change from Baseline in BSA Affected by Psoriasis at Weeks 16 and 24 Comparing TAK-279 Against Apremilast

    Psoriasis BSA will be assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represents 1% BSA. The sum of handprints equates to the total surface area of involvement.

    Time frame: Baseline, Weeks 16 and 24

  32. Percent Change from Baseline in BSA Affected by Psoriasis at Weeks 16 and 24 Comparing TAK-279 Against Apremilast

    Psoriasis BSA will be assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represents 1% BSA. The sum of handprints equates to the total surface area of involvement.

    Time frame: Baseline, Weeks 16 and 24

  33. Percentage of Participants Achieving an sPGA of Clear (0) at Week 24 Comparing TAK-279 Against Apremilast

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' will include all participants who score a 0.

    Time frame: Week 24

  34. Percentage of Participants with a Baseline DLQI Score >=2 who Achieve a DLQI Score of 0/1 at Week 24 Comparing TAK-279 Against Apremilast

    The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicate: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life).

    Time frame: Week 24

  35. Percentage of Participants with a Baseline PSSD >=1 who Achieve a Weekly Mean PSSD Symptom Score of 0 at Week 24 Comparing TAK-279 Against Apremilast

    The PSSD is an 11-item validated questionnaire that assesses symptoms (itch, pain, stinging, burning, and skin tightness) and participant-observable signs (skin dryness, cracking, scaling, shedding/flaking, redness, and bleeding) of moderate-to-severe plaque psoriasis. These symptoms and signs will be evaluated by asking participants to assign a numerical score representing of worst intensity over the last 24-hour on a scale from 0 to 10, with 0 indicating absence of symptoms or signs and 10 indicating worst imaginable symptoms or signs. The PSSD is a composite score calculated based on the scores for each question that can range between 0 and 100. A higher score indicates more severe disease.

    Time frame: Week 24

  36. Change from Baseline in ssPGA at Weeks 16 and 24 Comparing TAK-279 Against Apremilast

    ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions will be evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicate worsening.

    Time frame: Baseline, Weeks 16 and 24

  37. Percentage of Participants Achieving a PGA of the Hands and/or Feet of Clear (0) or Almost Clear (1) with a >=2-Point Decrease From Baseline at Weeks 16 and 24 Comparing TAK-279 Against Apremilast

    PGA is a 5-point scale and a score of 0 to 4 should be assigned, based on the category that best describes the severity of active psoriasis of the participant's hands and/or feet (palmoplantar), where 0=clear and 4=severe. Higher scores indicate worsening of severity. It will be evaluated for participants with the presence of active hand or foot psoriasis on Day 1.

    Time frame: Baseline, Weeks 16 and 24

  38. Change from Baseline in SF-36 Version 2 Scores at Weeks 16 and 24 Comparing TAK-279 Against Apremilast

    The SF-36 is a self-administered, validated questionnaire designed to measure generic health-related QoL. This 36-item questionnaire measures 8 domains, including physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health, physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Two summary scores, including the PCS and MCS, will be calculated ranging from 0 (worst) to 100 (best). Higher scores indicate better QoL.

    Time frame: Baseline, Weeks 16 and 24

  39. Change from Baseline in the EQ-5D-5L Scores at Weeks 16 and 24 Comparing TAK-279 Against Apremilast

    EQ-5D-5L includes 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and 5 response levels for each domain (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems). The scores in the 5 dimensions will be summarized into a health state index score. The health state index value is a single value on a scale from less than 0 to 1 (negative values are valued as worse than dead) with higher scores indicating better health; 0=a health state equivalent to death, and 1=perfect health.

    Time frame: Baseline, Weeks 16 and 24

  40. Change from Baseline in the WPAI-PSO Scores at Weeks 16 and 24 Comparing TAK-279 Against Apremilast

    The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism and impairment in activities performed outside of work. Each WPAI score will be expressed as impairment percentages (0-100) with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.

    Time frame: Baseline, Weeks 16 and 24

  41. Percentage of Participants Achieving an sPGA of Clear (0) or Almost Clear (1) with a >=2-Point Decrease from Baseline at Weeks 24, 40, and 52 Comparing TAK-279 Against Apremilast

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' and 'Almost clear' will include all participants who score a 0 or 1.

    Time frame: Baseline, Weeks 24, 40 and 52

  42. Percentage of Participants Achieving PASI-75 at Weeks 24, 40, and 52 Comparing TAK-279 Against Apremilast

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Weeks 24, 40 and 52

  43. Percentage of Participants Achieving PASI-90 at Weeks 24, 40, and 52 Comparing TAK-279 Against Apremilast

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: Weeks 24, 40 and 52

  44. Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESI)

    TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the study intervention or medicinal product. An AESI (serious or nonserious) is an adverse event of scientific and medical concern specific to the compound or program, for which ongoing monitoring and rapid communication by the investigator may be appropriate.

    Time frame: Up to Week 56

  45. Number of Participants with Clinically Significant Vital Signs

    Time frame: Up to Week 56

  46. Number of Participants with Clinically Significant Laboratory Values

    Time frame: Up to Week 56

  47. Number of Participants with Clinically Significant Electrocardiogram (ECG) Findings

    Time frame: Up to Week 56

07

Study locations

132 sites
  • Saguaro Dermatology Associates, LLC - Probity - PPDS
    Phoenix, Arizona 85008-3884, United States
  • First OC Dermatology - Fountain Valley
    Fountain Valley, California 92708-3701, United States
  • Center for Dermatology Clinical Research
    Fremont, California 94538-1614, United States
  • UCLA University of California Los Angeles
    Los Angeles, California 90024, United States
  • UC Davis Dermatology Clinic
    Sacramento, California 95816-3370, United States
  • Driven Research LLC
    Coral Gables, Florida 33134-3901, United States
  • FXM Clinical Research Ft. Lauderdale, LLC
    Fort Lauderdale, Florida 33308-5211, United States
  • Direct Helpers Research Center
    Hialeah, Florida 33012-3618, United States
  • FXM Clinical Research Miami, LLC
    Miami, Florida 33175-3582, United States
  • Renstar Medical Research -21 NE 1st Ave
    Ocala, Florida 34470-6657, United States
  • Marietta Dermatology & The Skin Cancer Center - Marietta
    Marietta, Georgia 30060-7902, United States
  • Leavitt Clinical Research - 1542 Elk Creek Dr
    Idaho Falls, Idaho 83404-8322, United States
  • Arlington Dermatology
    Rolling Meadows, Illinois 60008-3811, United States
  • Dawes Fretzin Clinical Research Group-7910 N Shadeland Ave
    Indianapolis, Indiana 46256-4697, United States
  • Kindred Hair & Skin Center - CAR
    Columbia, Maryland 21046-1246, United States
  • Revival Research Corporation - Michigan - ClinEdge - PPDS
    Troy, Michigan 48084-3536, United States
  • Grekin Skin Institute
    Warren, Michigan 48088-3671, United States
  • Henderson Clinical Trials
    Henderson, Nevada 89052-5016, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03766-1937, United States
  • ALLCUTIS Research, LLC.
    Portsmouth, New Hampshire 03801-6822, United States
  • Northwell Health Physician Partners Dermatology at Lake Success - BRANY - PPDS
    New York, New York 10003-3314, United States
  • Accellacare of Cary
    Cary, North Carolina 27518-7414, United States
  • Bexley Dermatology Research - Probity - PPDS
    Bexley, Ohio 43209, United States
  • Clinical Research Center of the Carolinas, LLC
    Charleston, South Carolina 29407-5347, United States
  • International Clinical Research-Tennessee LLC
    Murfreesboro, Tennessee 37130-2450, United States
  • Bellaire Dermatology Associates
    Bellaire, Texas 77401-3505, United States
  • Progressive Clinical Research PA - San Antonio
    San Antonio, Texas 78213-2250, United States
  • St George Dermatology and Skin Cancer Center - Probity - PPDS
    Kogarah, New South Wales 2217, Australia
  • The Skin Center - Probity - PPDS
    Benowa, Queensland 4217, Australia
  • Veracity Clinical Research Pty Ltd
    Brisbane, Queensland 4102, Australia
  • Skin Health Institute Inc - Probity - PPDS
    Carlton, Victoria 3053, Australia
  • Sinclair Dermatology-East Melbourne
    East Melbourne, Victoria 3002, Australia
  • Alfred Health
    Parkville, Victoria 3004, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Beacon Dermatology - Probity - PPDS
    Calgary, Alberta T3A 2N1, Canada
  • Enverus Medical Research - Probity - PPDS
    Surrey, British Columbia V3R 6A7, Canada
  • CCA Medical Research - Probity - PPDS
    Ajax, Ontario L1S 7K8, Canada
  • SimcoDerm Medical and Surgical Dermatology Centre - Probity - PPDS
    Barrie, Ontario L4M 7G1, Canada
  • Kingsway Clinical Research - Probity - PPDS
    Etobicoke, Ontario M8X 1Y9, Canada
  • Guelph Dermatology Research - Probity - PPDS
    Guelph, Ontario N1H 1B1, Canada
  • Mediprobe Research Inc
    London, Ontario N5X 2P1, Canada
  • North Bay Dermatology Center - Probity - PPDS
    North Bay, Ontario P1B 3Z7, Canada
  • North York Research Inc. - Probity - PPDS
    North York, Ontario M2M 4J5, Canada
  • Research Toronto - Probity - PPDS
    Toronto, Ontario M4W 2N4, Canada
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100044, China
  • Beijing Friendship Hospital, Capital Medical University - PPDS
    Beijing, Beijing Municipality 100050, China
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
  • Beijing Tongren Hospital, Capital Medical University
    Beijing, Beijing Municipality 100730, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 400016, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350005, China
  • Dermatology Hospital of Southern Medical University
    Guangzhou, Guangdong 510091, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510120, China
  • Zhujiang Hospital of Southern Medical University
    Guangzhou, Guangdong 510280, China
  • The University of Hong Kong - Shenzhen Hospital
    Shenzhen, Guangdong 518053, China
  • The First Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050031, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430060, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia 750004, China
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710004, China
  • Shandong Provincial Hospital
    Jinan, Shandong 250021, China
  • Shanghai Skin Disease Hospital
    Shanghai, Shanghai Municipality 200020, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang 310000, China
  • The 1st Affiliated Hospital of Wenzhou Medical University - Nanbaixiang Campus
    Wenzhou, Zhejiang 325000, China
  • Hautarztpraxis Mahlow
    Blankenfelde-Mahlow, Brandenburg 15831, Germany
  • Klinikum Oldenburg AöR
    Oldenburg, Lower Saxony 26133, Germany
  • Universitätsklinikum Münster
    Münster, North Rhine-Westphalia 48149, Germany
  • Universitätsklinikum Schleswig-Holstein - Campus Lübeck
    Lübeck, Schleswig-Holstein 23562, Germany
  • ASL 1 L'Aquila - Presidio Ospedaliero San Salvatore
    L’Aquila, Abruzzo 67100, Italy
  • Azienda Ospedaliera Universitaria Luigi Vanvitelli - Via Pansini 5
    Naples, Campania 80131, Italy
  • IRCCS Az. Osp. Universitaria San Martino- IST
    Genoa, Liguria 16132, Italy
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico -Via Pace 9
    Milan, Lombardy 20122, Italy
  • IRCCS Istituto Clinico Humanitas
    Rozzano, Lombardy 20089, Italy
  • IRCCS Policlinico San Donato
    San Donato Milanese, Lombardy 20097, Italy
  • Presidio Ospedaliero Gaspare Rodolico
    Catania, Sicily 95123, Italy
  • Azienda Usl Toscana Centro - Firenze
    Florence, Tuscany 50125, Italy
  • Nagoya City University Hospital
    Nagoya, Aiti 467-0802, Japan
  • Takagi Dermatological Clinic
    Obihiro-Shi, Hokkaidô 080-0013, Japan
  • JR Sapporo Hospital
    Sapporo, Hokkaidô 060-0033, Japan
  • Medical Corporation Kojinkai Sapporo Skin Clinic
    Sapporo, Hokkaidô 060-0063, Japan
  • Fukuoka University Hospital
    Fukuoka, Hukuoka 814-0180, Japan
  • Saruwatari Dermatology Clinic
    Kagoshima, Kagoshima-ken 892-0826, Japan
  • Tokai University Hospital
    Isehara-Shi, Kanagawa 259-1143, Japan
  • Jichi Medical University Hospital
    Shimotsuke-Shi, Tochigi 329-0431, Japan
  • Teikyo University Hospital
    Itabashi-Ku, Tokyo 173-0003, Japan
  • Tokyo Medical University Hospital
    Shinjuku-Ku, Tokyo 160-0023, Japan
  • JCHO Tokyo Yamate Medical Center
    Shinjuku-Ku, Tokyo 169-0073, Japan
  • Tokyo Teishin Hospital
    Sumida-Ku, Tokyo, Japan
  • Ohyama Dermatology Clinic
    Kumamoto, 861-4101, Japan
  • Dermatology and Ophthalmology Kume Clinic
    Sakaishi, Ôsaka 593-8324, Japan
  • AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Poznaniu
    Poznan, Greater Poland Voivodeship 60-702, Poland
  • Cityclinic Przychodnia Lekarsko Psychologiczna Matusiak Spółka Partnerska
    Wroclaw, Lower Silesian Voivodeship 50-566, Poland
  • Clinical Best Solutions - Lublin
    Lublin, Lublin Voivodeship 20-078, Poland
  • Dermoklinika-Centrum Medyczne s.c
    Lódz, Lódzkie 90-436, Poland
  • Rheumatology Clinic NZOZ Lecznica MAK-MED
    Nadarzyn, Masovian Voivodeship 05-830, Poland
  • Clinical Best Solutions - Warszawa
    Warsaw, Masovian Voivodeship 00-710, Poland
  • MICS Centrum Medyczne Warszawa - MICS - PPDS
    Warsaw, Masovian Voivodeship 00-874, Poland
  • High-Med Przychodnia Specjalistyczna
    Warsaw, Masovian Voivodeship 01-817, Poland
  • Klinika Reuma Park sp . zoo Sp.k.
    Warsaw, Masovian Voivodeship 02-665, Poland
  • Klinika Ambroziak - Kosiarzy 9A
    Warsaw, Masovian Voivodeship 02-953, Poland

Showing the first 100 of 132 sites across 10 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jan 2025, 14 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 14 months is close to that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2023
First posted
Oct 18, 2023
StartActual
Nov 6, 2023
Primary completionActual
Jan 22, 2025
CompletionActual
Oct 22, 2025
Results delay requested
Oct 2, 2025
Last update
Oct 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06088043
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Oct 18, 2023
Start date
Nov 6, 2023
Primary completion
Jan 22, 2025
Completion
Oct 22, 2025
Last update
Oct 24, 2025

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zasocitinib

Start the discussion